Miscellaneous
CME Available: https://auau.auanet.org/node/33910 At the conclusion of this course, participants will be able to: 1. Implement current practice guidelines into the office setting. 2. Identify the best intravesical agent and duration of therapy for low, intermediate, and high risk settings and what to do during a BCG shortage. 3. Identify methods to treat significant toxicities from various intravesical therapies. 4. Define high risk scenarios that necessitate cystectomy and options for BCG-unresponsive disease. ACKNOWLEDGEMENTS Independent educational grant support provided by: AstraZeneca Bristol-Myers Squibb Merck